Hibarimicin H
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Enzyme inhibitors |
| Catalog number | BBF-00959 |
| CAS | |
| Molecular Weight | 1527.56 |
| Molecular Formula | C75H98O33 |
Online Inquiry
Description
Hibarimicin H is a tyrosine kinase inhibitor produced by Microbispora rosea subsp. hibaria.
Specification
| IUPAC Name | (2S,4S,5S,6R,7S,8R,9S)-15-[(6aR,7S,8R,9S,10S,10aS)-7-[(2R,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-1,8,10,10a,12-pentahydroxy-9-[(2R,5R,6S)-5-hydroxy-6-methyloxan-2-yl]oxy-3,4-dimethoxy-11-oxo-10-propyl-6a,7,8,9-tetrahydro-6H-tetracen-2-yl]-7-[(2R,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-6,9,12,19-tetrahydroxy-5-[(2R,5R,6S)-5-[(2S,5S,6R)-5-hydroxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-16-methoxy-4-propyl-3-oxapentacyclo[9.8.0.02,8.04,9.013,18]nonadeca-1(11),12,15,18-tetraene-10,14,17-trione |
| Canonical SMILES | CCCC1(C(C(C(C2C1(C(=O)C3=C(C4=C(C=C3C2)C(=C(C(=C4O)C5=C(C(=O)C6=C(C7=C(C(=C6C5=O)O)C(=O)C8(C9C7OC8(C(C(C9OC1CC(C(C(O1)C)O)O)O)OC1CCC(C(O1)C)OC1CCC(C(O1)C)O)CCC)O)O)OC)OC)OC)O)O)OC1CC(C(C(O1)C)O)O)O)OC1CCC(C(O1)C)O)O |
| InChI | InChI=1S/C75H98O33/c1-11-19-72(92)70(106-39-17-14-34(77)26(4)99-39)60(88)63(104-41-23-35(78)52(80)28(6)101-41)32-22-30-21-31-44(54(82)43(30)68(90)74(32,72)93)55(83)48(66(97-10)62(31)95-8)47-56(84)45-46(59(87)65(47)96-9)57(85)49-50(58(45)86)69(91)75(94)51-64(49)108-73(75,20-12-2)71(61(89)67(51)105-42-24-36(79)53(81)29(7)102-42)107-40-18-15-37(27(5)100-40)103-38-16-13-33(76)25(3)98-38/h21,25-29,32-42,51-53,60-61,63-64,67,70-71,76-83,85-86,88-89,92-94H,11-20,22-24H2,1-10H3/t25-,26+,27+,28-,29-,32-,33+,34-,35+,36+,37-,38+,39-,40-,41-,42-,51-,52-,53-,60-,61-,63+,64-,67+,70+,71+,72+,73+,74-,75-/m1/s1 |
| InChI Key | HTJVZFDAFDUEEM-QGLZJUOQSA-N |
Properties
| Appearance | Red Powder |
Reference Reading
1. Effects of hibarimicins and hibarimicin-related compounds produced by Microbispora on v-Src kinase activity and growth and differentiation of human myeloid leukemia HL-60 cells
Sung Ig Cho, Hidesuke Fukazawa, Yoshio Honma, Takayuki Kajiura, Hiroshi Hori, Yasuhiro Igarashi, Tamotsu Furumai, Toshikazu Oki, Yoshimasa Uehara J Antibiot (Tokyo). 2002 Mar;55(3):270-8. doi: 10.7164/antibiotics.55.270.
We studied the effects of hibarimicins and hibarimicin-related compounds produced by Microbispora rosea subsp. hibaria [glycosides (hibarimicins A, B, C, D, E, G, H and I) and aglycon (hibarimicinone)] or compounds produced by its mutants [glycosides (HMP-P4 and -Y6), aglycons (HMP-P1 and -Y1) and shunt products (HMP-M1, M2, M3 and -M4)] on v-Src tyrosine kinase and growth and differentiation of human myeloid leukemia HL-60 cells. Among them, hibarimicin B was a strong and the most selective v-Src kinase inhibitor with differentiation inducing activity of HL-60 cells. Hibarimicin E similarly induced HL-60 cell differentiation but had no v-Src kinase inhibitory activity. Hibarimicinone was the most potent v-Src kinase inhibitor, although less selective, and did not induce differentiation of HL-60 cells. Hibarimicin B competitively inhibited ATP binding to the v-Src kinase, but hibarimicinone showed noncompetitive inhibition. These two compounds, however, showed similar mixed types of inhibition against a Src substrate binding to the v-Src kinase. Altogether, these results suggest that signaling molecules other than Src might be more important in the differentiation induction of HL-60 cells.
Recommended Products
| BBF-00677 | 3-Amino-3-deoxy-D-glucose | Inquiry |
| BBF-03755 | Actinomycin D | Inquiry |
| BBF-03754 | Castanospermine | Inquiry |
| BBF-02642 | Lactonamycin | Inquiry |
| BBF-01693 | Doxorubicin EP Impurity A (Daunorubicin) | Inquiry |
| BBF-03753 | Baicalin | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
